Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSCC_ASC in Ischemic Heart Disease and Heart Failure
NCT02387723Phase 1Completed
- Sponsor
- Cell2Cure
- Start
- Dec 2014
- Primary completion
- Nov 2015
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CSCC_ASC in heart failure (HF) and ischemic heart disease (IHD), sponsored by Cell2Cure. Primary endpoints: Serious Adverse Events at 6 months and Tissue antibodies towards donor cells at 6 months. Started Dec 2014; status: completed.
02
Drugs
CSCC_ASC
03
Conditions
heart failure (HF)ischemic heart disease (IHD)
Beyond the preview
Go deeper on NCT02387723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02387723.